Conduit Pharmaceuticals (CDT) said Wednesday it has regained compliance with Nasdaq's minimum bid price and stockholders' equity requirements, citing a notification from the stock exchange.
The biopharmaceutical company said Nasdaq's hearing panel has implemented a one-year Discretionary Panel Monitor starting May 15 to ensure long-term compliance.
Shares of the company were more than 3% higher in recent premarket activity.